Format

Send to

Choose Destination
Expert Opin Ther Pat. 2018 Sep;28(9):679-689. doi: 10.1080/13543776.2018.1514011. Epub 2018 Sep 7.

5-HT1A receptor ligands and their therapeutic applications: review of new patents.

Author information

1
a Institute of Pharmacology, Polish Academy of Sciences , Kraków , Poland.

Abstract

INTRODUCTION:

5-HT1AR was one of the first discovered serotonin receptors and is one of the most thoroughly studied. Dysfunctions associated with 5-HT1AR neurotransmission are linked to several psychiatric disorders, including anxiety, depression, and movement disorders.

AREAS COVERED:

The current review covers patent literature published between January 2012 and May 2018. Queries were performed on Espacenet, SciFinder, clinicaltrials.gov, pharmacodia.com, and the websites of pharmaceutical companies.

EXPERT OPINION:

Several novel therapeutic applications have been proposed for 5-HT1AR ligands, i.e. prostate cancer treatment, gastrointestinal and cardiopulmonary disorders, facilitation of urination and defecation, and L-DOPA-induced dyskinesia. Interestingly, no patent application has been filed by big pharma companies, while numerous researches are being conducted in smaller companies and academia.

KEYWORDS:

5-HT1A; agonist; antagonist; serotonin modulator; serotonin receptor; therapeutic patent

PMID:
30124346
DOI:
10.1080/13543776.2018.1514011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center